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ABSTRACT
This paper describes the burden of receiving immunoglob-
ulin (Ig) treatment from the perspective of patients diagnosed
with a Primary Immunodeficiency (PID). Thirty semi-structured
interviews with patients receiving intravenous (n=21) and sub-
cutaneous immunoglobulin (n=9) therapy, either at home or in
hospital were undertaken. Underpinned by a phenomenological
theoretical framework, and using a qualitative, inductive the-
matic approach to prioritise patients’ concerns, we identified that
Ig treatment requires considerable effort by the patient, partic-
ularly in relation to the amount of time, organization and plan-
ning that is needed. They also face numerous physical, social,
relationship, emotional, role functioning, travelling, and finan-
cial challenges in their effort to undergo and maintain their in-
fusions and care for their health. Some qualitative differences
in treatment burden were noted between home and hospital set-
tings which contributed to non-adherence to those regimes. Im-
munoglobulin treatment burden is complex and influenced by
therapeutic mode and setting and the personal circumstances of
the patient. As choice over treatment method appears to be
mainly informed by lifestyle needs, PID patients may benefit
from more information about these potential Ig lifestyle influ-
ences when selecting which form of treatment to take together
with their health professional.
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Introduction
Primary Immunodeficiency Disorders (PIDs) consist
of a group of rare disorders characterised by an impair-
ment in the development and maturation of the immune
system.1 This means that for people affected by PIDs,
parts of their immune system are missing or not working
properly leaving them with a reduced or absent natural
defence against viruses, bacteria or fungi. The conse-
quences of this immune deficiency are that many people
with PIDs will experience frequent infections which do
not resolve as quickly as would be expected with antibi-
otic treatment and even then, the infections may keep re-
curring.1,2 These symptoms can be mild e.g. recurrent
colds or severe illnesses including pneumonia, skin dis-
orders, arthritis and heart problems to name a few.3 As
such, the symptom and disease burden associated with
PIDs often have a significant negative impact upon a pa-
tient’s quality of life.4 Children and adults can experience
frequent absenteeism from school or work, reduced par-
ticipation in social and sporting activities, as well as a
range of psychological symptoms in response to living
and coping with their condition.2 
Immunoglobulin (Ig) treatment is the main therapy for
most patients with PID and it is typically administered ei-
ther intravenously (directly into a vein) or subcutaneously
(directly under the skin). Whilst it is generally accepted
that this treatment can dramatically improve quality of
life,1,5 it may also be associated with a substantial treat-
ment burden i.e. work and effort for the patient. For ex-
ample, intravenous Ig treatment (IVIg) is typically
administered in hospital (although it can also be given at
home in some circumstances). It is usually infused every
3 weeks but can range from 2 to 4 weeks lasting approx-
imately 2-4 hours per visit. The precise length of infusion
however, will be dependent on dose and tolerance of the
individual. Side effects include headache, feeling hot,
nausea, diarrhoea, rash, back pain, rarely hypotension. Ex-
tremely rare and serious side effects such as allergic re-
actions, kidney problems or blood clots. Subcutaneous
Immunoglobulin (SCIg) infusions are given by slowly in-
jecting immunoglobulin into fatty tissue just underneath
the skin. SCIg can be given at home, using a mechanical
infusion pump (spring loaded, or battery powered) or by
rapid push (a manual method that does not require a
pump, infusion is pushed by hand through a syringe). The
use of the latter method has been increasing over time.
Common side effects to SCIg include site reactions such
as redness, swelling and itching which are usually mild
and go away over a day or two. Subcutaneous Ig treatment
(SCIg) is typically administered 1-3 times per week in the
home but can be administered in the hospital depending
on patients’ individual needs, but this is generally consid-
ered the exception rather than the rule.6
The ‘work of being a patient’ is referred to as burden
of treatment – everything the patient needs to do to treat
and manage their illness, for example undergoing tests
and investigations, visiting doctors, adhering to treatment
regimens and making lifestyle changes.7 Burden of treat-
ment is a concept independent of the disease burden and
can be defined as the consequences of receiving treatment
(these may be medication, therapies or other interven-
tions).8-10 It is an important concept because it may nega-
tively affect adherence to treatment, quality of life, disease
management and health care outcomes such as hospitali-
sations and survival.11,12
Whilst there are numerous studies which have tried to
measure the quality of life of patients with a PID,1,5,13-22
less attention has focused upon the burden of Ig treatment.
A recent systematic review which synthesised the evi-
dence regarding the potential burden of Ig treatment found
that overall, PID patients reported little Ig treatment bur-
den and appeared satisfied with IVIg and SCIg therapy.23
The patients’ preference appeared to be the delivery of the
Ig treatment in the patient’s home and SCIg was preferred
after switching from IVIg therapy. However, most studies
had adopted a quantitative approach using questionnaires
and there was a lack of qualitative research which, when
applied in a health service setting, has the potential to gain
a richer and deeper insight into the patient’s lived experi-
ence with an illness or treatment – particularly if the con-
dition is chronic in nature.24 For this reason, the lack of
qualitative research in this area was considered an impor-
tant gap in the literature. One recent mixed-method study
undertook a qualitative exploration of Facilitated Subcu-
taneous Immunoglobulin (fSCIg) to explore treatment
burden and analysed patient’s responses to open-ended
questions using a thematic analysis. However, the study
included patients with both a primary and secondary im-
munodeficiency receiving fSCIG, and unfortunately did
not report the findings separately for these different pa-
tient groups. Nevertheless, these patients described expe-
riencing some immediate post treatment symptoms such
as fatigue, and difficulties using the infusion equipment.
But, overall low treatment burden was reported due to the
time-saving nature of the treatment and overall improve-
ments to health and well-being that occurred, thus out-
weighing any negative aspects associated with the
treatment.25
Aims
Therefore, the aims of this paper are to describe the
results of a qualitative, cross-sectional study carried out
to explore in-depth the burden of treatment i.e. the ‘work
of being a patient’, for patients diagnosed with a PID and
undergoing Ig treatment. To the best of our knowledge,
this is the first study which has solely sought to provide a
rich insight into the potential burden of Ig treatment for
this patient group. As the aim was to understand the pa-
tient’s lived experience of Ig treatment burden, we used a
phenomenological theoretical approach to guide the in-














Materials and Methods 
Study design 
In order to gain an in-depth understanding of the bur-
den of Ig treatment for patients with a PID we adopted a
qualitative methodology. We conducted thirty semi-struc-
tured interviews with patients receiving intravenous
(n=21) and subcutaneous immunoglobulin (n=9) therapy,
either at home or in hospital and we approached patients
attending the Clinical Immunology and Allergy unit
(CIAU) at a hospital in Yorkshire, UK between March
2015 to October 2015 to participate in the study. Ethics
approval for our study was granted from the NRES com-
mittee Yorkshire and the Humber – Bradford Leeds on
31st October 2014. The REC reference was 14/YH/1247. 
Participant selection 
Our inclusion criteria were that patients aged 16 years
and older, who had been diagnosed with a PID and were
undergoing Ig treatment (either SC, IV at home or in hos-
pital). We excluded patients if they were receiving Ig
treatment for a secondary immunodeficiency e.g. second-
ary to lymphoproliferative disease or following treatment
with immunosuppression or if their medical condition
meant that they were unable to undertake an interview.
Participant recruitment 
Our members of the clinical care team (FA, AS and
DH) identified patients from the PID patient database held
at the Clinical Immunology and Allergy Unit. They posted
the patient information sheets and a consent form to po-
tential participants with a pre-paid addressed envelope to
return to the clinic if they were interested in taking part.
The clinic team then passed onto the researcher the details
of those who had returned the completed consent form.
We asked patients whether they had received the posted
information when they attended for appointments. We did
not provide incentives to patients to participate in the
study, but we did reimburse their travel and/or parking
costs. Our researchers (RD or JH) then visited the patient
in the hospital on their infusion date if they were hospital
- based or at home to undertake the interviews. 
Interview guide development
We developed a semi-structured interview schedule to
help researchers guide the conversation and keep respon-
dents on topic as well as to encourage two-way communi-
cation. Our semi-structured interview schedule also
provided an opportunity for the interviewers to capture not
only the answers to questions, but also learn about the rea-
sons behind the answers, as well as allowing respondents
time to open up about sensitive issues. We initially gener-
ated the questions for the interview schedule following i) a
meeting with some members of the team which involved
academic, clinical and patient advocates, and ii) by the
emerging results of a systematic review. Some members of
our team were undertaking this in parallel to the qualitative
study, which had started to identify the areas of Ig treatment
burden for patients with a PID from the international liter-
ature.24Our initial schedule was then circulated to the wider
team for final internal peer review and feedback following
which minor amendments were made. 
Data collection process 
We used a purposive sampling method whereby pa-
tients were approached for participation in the study to
ensure maximum diversity within the sample, to reflect
gender, a range of age groups, a variety of PID conditions,
length from diagnosis of PID, length of time on treatment
and types and modes of treatment (i.e. infusing at home
or hospital). We anticipated that interviews with 25-30 pa-
tients may be needed to reach data saturation, although,
we agreed that recruitment would continue until thematic
saturation was achieved.
In broad terms, saturation is used in qualitative re-
search as a standard for discontinuing data collection
and/or analysis. Saturation guides acceptance across a
range of approaches to qualitative research and is often
proposed as an essential methodological element within
such work. Failure to reach saturation has an impact on
the quality of the research conducted and it is considered
to be the gold standard by which purposive sample sizes
are determined in health science research.26 Saturation is
commonly described as a rule of qualitative research, and
it features in a number of generic quality criteria for qual-
itative methods. The saturation model used in this study
is aligned with the data analysis approach as it is focused
on the identification of new themes. More specifically, it
is based on the number of such themes rather than the
completeness of existing theoretical categories. This ap-
proach is termed inductive thematic saturation and can be
described as extent to which ‘new’ codes or themes are
identified within the data, and/or the extent to which new
theoretical insights are gained from the data via this
process.26
It has been established in the qualitative methods lit-
erature that saturation can be reached with sample size as
small as 12 participants.26 However, in our study satura-
tion was reached by the 30th interview as it was agreed by
the data analysts that the inclusion of additional study par-
ticipants did not provide any substantially new or previ-
ously unrecognized issues or concepts. Our data analyst
team members carefully monitored the point when satu-
ration was achieved throughout the qualitative data analy-
ses by populating a tabular summary known as a
saturation grid. 
Two of our researchers undertook the interviews (RD
and JH). RD is a psychologist and JH is an experienced
health service researcher. They had both received training
in qualitative research methodology. Patients receiving













their treatment in hospital were offered the option of being
seen at home if they preferred.
Considerable efforts were undertaken by us to establish
the research’s trustworthiness as defined by Lincoln and
Guba.27 For example, we have presented rich quotes to sup-
port the themes derived in order to support findings in other
contexts (transferability). In addition, we kept a detailed
audit trail of the data generated and used as part of the study
(e.g. the interview transcripts, audio recordings and coding
framework and system) which several members of our re-
search team reviewed (dependability). It could be argued
that the confirmability (objectivity) of the research findings
may be compromised as the funder of the research is a man-
ufacturer of Ig products. However, the funder of our re-
search did not have any involvement in the data collection
and analysis process and the transcriptions and audio
recordings were not shared with these team members. The
members of our study team that were specifically involved
in the data collection and analysis (GJ, RD, JH and EH)
were from academic institutions and were not responsible
for the clinical treatment and management and/or personal
care of any of the patients that took part.
We recorded the interviews using the Olympus DS-
700 digital voice recorder and transcribed these verbatim
(names and identifiable information were not included in
the transcripts). An independent transcriber (not part of
the study team) undertook the transcriptions. Members of
our research team checked the quality of these and as-
sisted the transcriber where clarification was needed (e.g.
the sound was too quiet, and/or unfamiliar clinical words
were used). We uploaded the transcripts into NVivo ver-
sion 10 for data management and analysis. 
Data analysis 
Qualitative data analysis is a broad term encompassing
different analytical approaches with the aim of providing
contextual description and interpretation of social phe-
nomenon.28 Qualitative content analysis (QCA) and the-
matic analysis (TA) are both classified under the
qualitative descriptive design and are widely used by
qualitative researchers. TA are similar to QCA in terms of
philosophical backgrounds, immersion in data, attention
to both description and interpretation of data analysis,
consideration of context during data analysis, and cutting
across data for seeking themes. As a point of difference,
within TA, a theme is considered to be latent content, but
QCA researchers are free to decide between the level of
data analysis when developing the category or the theme.
Nevertheless, to develop a theme in both of these ap-
proaches, iterative or forward-backward movements and
comparison of code clusters in relation to the whole data
are required.28,29
Researchers using QCA may prefer to work with sim-
plicities and overt data by going through a large amount
of text to obtain easy-achieved classifications and mani-
fest contents to develop categories. On the other hand,
those using TA require an exhaustive and non-stop process
of abstraction and in-depth analysis from the beginning
to reach the theme.28 It is believed that high-quality qual-
itative research is marked by a thick description, and rich
complexity of findings rather than deductive precision.
The complexity and aesthetic aspects of the theme can
motivate readers to reflect on data and relate the findings
to their own personal perspectives. Analysing data quali-
tatively and also quantifying data are possible in QCA,
but in TA a purely qualitative account of data is utilized.29
Based on the description above, we adopted an inductive
[data-driven] thematic analysis approach to prioritise pa-
tient accounts/concerns and identify the key concepts and
themes. We also selected the TA approach because it is
likely to enable for production of more trustworthy and
insightful findings by providing a rich and detailed, yet
complex account of the patient data.28
Friese reports that using qualitative software to
analyse data does not diminish the quality of the qualita-
tive research nor does it simplify the whole process of
doing qualitative research. When used correctly, it can ac-
tually ease the data management and data analysis
processes and facilitate analytic rigor.30 As NVivo pro-
vides a valuable tool for analysing the interviews themat-
ically, NVivo version 10 was used for both effective data
management and analysis. However, it should be noted
that NVivo software can only help the researcher to man-
age, explore and find patterns in data but it cannot replace
the analytical expertise. 
In the data-driven thematic analysis approach adopted
in this study, the categories (codes) were selected based
on a detailed analysis of all data. This approach was par-
ticularly suitable as the goal was to make an in-depth ex-
ploration of the data. Coding of the data into the
categories of analysis required the execution of an explicit
set of recording instructions about the rules for coding the
data into categories. This process involved more than one
judge as the process of triangulation common in qualita-
tive research is designed to enhance the quality of and
confidence in the analysis.28
More specifically, four transcripts were read independ-
ently by two researchers (RD and GJ) to produce an initial
coding framework. A meeting was held to discuss and
agree the modifications to the framework. One researcher
(RD) then went through the other 26 transcripts and coded
using this framework, also adding new codes as they
arose. Units of text that clustered together were then
grouped into analytic categories - themes. It is important
to note that, if appropriate, the same unit of text was in-
cluded in more than one category. The data were then sys-
tematically revisited to ensure that a named theme had all
data relevant to support the topic included.
Given the under-researched nature of the topic, and
specifically of the presentation of the voices of those un-
dergoing Ig therapy, we have chosen to include rich per-
sonal testimony in the form of quotations within the















results section in order to ensure that the voices of a group
we rarely hear from, are in this context, heard.
Results
We sent fifty-two PID patients a participant informa-
tion sheet and consent form, of whom 35 (68%) consented
to take part in the study. In total, we conducted 30 semi-
structured interviews either in patient’s homes or at the
CIAU between March 2015 and October 2015. We
stopped interviewing at this point, because data saturation
was reached and therefore the remaining five patients
were not interviewed. We present the clinical character-
istics of the patient sample in Table 1 and a summary of
their demographics in Table 2. 
Burden of Ig treatment themes
In the effort to undergo and maintain Ig infusions and
care for their health, we generated eight themes to de-
scribe patients’ experiences of treatment: i) time burden;
ii) treatment consequences; iii) impact on social interac-
tions and relationships; iv) treatment environment; v) af-
fects emotional well-being; vi) travel; vii) role
functioning; and viii) financial consequences. For each
patient quote we report the patient’s unique study number
= IDx, the mode and place of treatment = IV/SC,
home/hospital, and their gender=M/F.
i) Time burden
In this theme, we describe how Ig treatment negatively
impacted upon patients’ time and was the main burden of
Ig treatment described by patients. Embedded within this
theme were three subthemes including: i) It takes up too
much time; ii) Time management - planning and organis-
ing routines; and ii) Inconvenience/arranging timetables
around others.
It takes up too much time
A considerable amount of time and commitment was
required in order to undergo this treatment regardless of
the mode of Ig therapy and location (home or hospital).
The amount of time varied by mode and location of Ig
treatment administration. Generally, patients described
having to take at least a couple of hours to a day every
few weeks to receive treatment. For people taking SCIg,
treatment was administered more regularly than for peo-
ple taking IVIg treatment. For those on the highest dose
of SCIg this meant infusing twice a week. As well as the
weekly time burden, many of the patients had been infus-
ing over a number of years which exacerbated the time
burden:
“I think it’s just because I’ve been doing it for like
32/33 years, and that’s quite a big commitment
isn’t it, so that for me at times, I just get every three
weeks thinking ‘argh here we go again’, and I re-
ally wish I could have like a break, and not have
to do it this time, but I know I can’t, so I do.”
(ID24 IV Home/ M).
In addition, some patients felt that SCIg home therapy
was preferable to hospital treatment as it didn’t take up as
much time, as one participant described:
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Table 1. Clinical characteristics of the patient sample.
Patient characteristics                                                                                                                 N (%)
Mean age:                                                                                                          52.9 years (SD: 17.5, range: 27-92 years).
Gender:                              Male                                                                                                  13 (43.3)
                                          Female                                                                                              17 (56.7)
Treatment mode:               IVIg home                                                                                          5 (16.7)
                                          IVIg hospital                                                                                     16 (53.3)
                                          SCIg home                                                                                         8 (26.7)
                                          SCIg hospital                                                                                      1 (3.3)
Diagnosis:                          Common variable immune deficiency                                              20 (66.6)
                                          Specific antibody deficiency                                                              3 (10)
                                          Undefined antibody deficiency                                                          2 (6.6)
                                          Hypogammaglobulinemia                                                                  2 (6.6)
                                          X-linked agammaglobulinemia                                                          1 (3.3)
                                          Selective IgA deficiency*                                                                   1 (3.3)
                                          CD19 deficiency                                                                                 1 (3.3)
Duration of treatment:       <1 year                                                                                                 3 (10)
                                          1-5 years                                                                                           10 (33.3)
                                          6-10 years                                                                                          5 (16.7)
                                          >10 years                                                                                            12 (40)
*NB: Whilst the diagnosis of selective IgA deficiency is not an indication for immunoglobulin replacement therapy per se, this patient had recurrent sinus and ear infection with end organ
damage and chronic rhinosinusitis/conjunctivitis. A few patients with isolated IgA deficiency behave like panhypogammaglobulinaemia cases (i.e. more severe antibody deficiency’) and require














“It’s took a lot less time, not having to go to hos-
pital. You haven’t got to waste a day, or waste half
a day in the hospital, wasting doctor and nurses
time... but now I just go to work, come home one
day, have my tea, and then start this treatment
straight afterwards.” (ID35, IV home/M)
The way in which time was experienced in terms of
‘waiting’ or ‘wasting time’ in the hospital setting is in the
quote above, therefore juxtaposed against the relative
freedom and lack of constraints felt when the treatment
was at home, ‘in their own time’. 
Time management – planning and organising routines
Generally, other issues related to time were about the
need to plan and organise their own time effectively which
required considerable effort on behalf of the patient. Pa-
tients’ often described having to keep to a strict routine to
manage their treatment and frequently plan ahead, regard-
less of what mode of administration they were receiving:
“So I prepare- I’ve got this nice little table that I
use, and it’s easy to sterile and everything. I get
my delivery every three months. I make packs up.
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Table 2. Summary of the study participants demographics.
Interview number      Participant ID                        Male or Female         Age at time of interview     Treatment at home                   IV or SC
                                                                                                                                                                            or in hospital  
1                                            ID01                                            M                                       42                                  Hospital                                 IV 
2                                            ID02                                            M                                       27                                  Hospital                                 IV
3                                            ID03                                            F                                        55                                   Home                                   SC
4                                            ID04                                            M                                       52                                  Hospital                                  IV
5                                            ID06                                            M                                       70                                  Hospital                                  IV
6                                            ID09                                            M                                       77                                  Hospital                                 IV
7                                            ID11                                            M                                       36                                  Hospital                                  IV
8                                            ID12                                            M                                       34                                  Hospital                                  IV
9                                            ID13                                            M                                       29                                   Home                                   IV
10                                          ID14                                            F                                        58                                  Hospital                                 IV
11                                          ID15                                            F                                        57                                  Hospital                                  IV 
12                                          ID18                                            M                                       92                                  Hospital                                 SC
13                                          ID19                                            F                                        80                                  Hospital                                  IV
14                                          ID20                                            F                                        83                                  Hospital                                  IV
15                                          ID22                                            F                                        83                                  Hospital                                  IV
16                                          ID23                                            F                                        62                                  Hospital                                  IV
17                                          ID24                                            M                                       47                                   Home                                   IV
18                                          ID28                                            F                                        43                                   Home                                   IV
19                                          ID29                                            F                                        52                                   Home                                   SC
20                                          ID33                                            F                                        32                                   Home                                   SC
21                                          ID35                                            M                                       52                                   Home                                   IV
22                                          ID36                                            F                                        54                                   Home                                   SC
23                                          ID39                                            F                                        43                                   Home                                   SC
24                                          ID40                                            F                                        53                                   Home                                   SC
25                                          ID41                                            F                                        50                                   Home                                   SC
26                                          ID43                                            F                                        51                                   Home                                   IV
27                                          ID46                                            M                                       41                                  Hospital                                  IV
28                                          ID47                                            F                                        67                                  Hospital                                  IV
29                                          ID49                                            F                                        33                                   Home                                   SC













So everything I need for that week, so I make me
12 packs up ready.” (ID 36 SC Home/F).
For some, their routines involved their partners and
family members and treatment was woven into the struc-
ture and routines of their everyday lives, including fitting
around meals and other activities: 
“So like today he’s in Manchester. So as long as
he doesn’t get stuck in traffic, half an hour before
he’s due home, he’ll ring and say ‘I’ll be home in
half an hour, take your treatment out the fridge’.
By the time he’s come in and you know we’ve had
a cup of tea, it’s about room temperature. Connect
it up, and then what I do while it’s in my tummy, I
pop the machines in a handbag, put it over my
shoulder and I can still do tea“ (ID33 SC Home/F).
Emotionally, some participants found that the lack of
flexibility concerning when they had their Ig treatment
got them down at times. This was regardless of whether
people were having IVIg or SCIg treatment and the loca-
tion they were having the treatment. For example, one
participant explained: 
“I think I’ve got to that point where I know I’ve
got to have it, and I can’t escape it. Whereas I’ve
tried before, I know I can’t now, I think I’ve come
to terms with it” (ID12 IV hospital/M).
Another participant felt that receiving Ig treatment in
hospital was preferable given the additional pressure of
having to keep their home environment ready and suitable
for the treatment:
“It’s easier if you know you’re coming to hospital,
you know you’re going to have half a day. You just
turn up, you sit, you’re done, you go home. You
don’t have to worry about it. Whereas at home
you’re obviously, you’re in your home environ-
ment, various things come up. You’ve obviously
got to try and keep it consistent, you know, infu-
sion day, you know make sure obviously your
products out the fridge, make sure all your supplies
are there, it’s just more to think about. For me, this
is easier” (ID51, IV hospital/M).
Inconvenience/arranging timetables around others
Those patients receiving SCIg at home who rely on an
infusion partner also described the difficulty of fitting their
SCIg at home in with the other person’s schedule and having
to rely upon others to help facilitate treatment, because as
one participant reported: “You can’t infuse while you’re on
your own. So, what we do is we just sort of work it round
[husbands name] work timetable” (ID33, SCIg home F).
Another participant said:
“I childmind for my youngest daughter Monday,
Tuesday, Wednesday evenings only for an hour.
And it’s not the treatment’s fault. If transport is
late, I don’t get home on time to go and childmind.
So now they say, ‘oh is it your treatment week
mum?’ And I say, ‘yes it’s my treatment week”
(ID23 IV Hospital/F).
Therefore, some participants, and their families were
having to alter plans and make allowances for the disrup-
tion (or potential) disruption that treatment may bring.
Sometimes this specifically related to the act of treatment
itself, but also the experience of accessing the hospital and
specifically the need for hospital organized transport
which created knock on effects or inconveniences in their
own as well as their family’s lives. 
Treatment consequences 
This theme describes the ways that undergoing Ig
treatment impacted upon the physical health of patients.
A wide range of experiences with the medication was ex-
pressed by over half of the patients. Within this theme
were four key subthemes including: i) impact upon skin,
ii) side effects, and iii) tiredness and fatigue.
Impact on skin 
Many of these skin-related impacts arose from the use
of needles. In this respect, one female on subcutaneous
treatment shared that: “My veins aren’t very good, and
they had become scarred and it was getting harder and
harder to get cannula’s in” (ID39 SC Home/F).
Some patients reported that the treatment itself was
uncomfortable – whereas others described more specific
side effects such as sore sites from the infusion, bruising,
swelling and tightness. A couple of participants described
not liking the look of their infusion site due to the swelling
from treatment. Some patients who had been undergoing
Ig treatment for a long time described having scarring on
their veins:
“I get everything prepared and I do it, and it does
help, visualising it in that way. I hate afterwards
when I’ve finished, the site area is really sore, it’s
swollen and because I’ve got a scar from my belly
button down” (ID 36 SC Home/F).
Side effects
Some, although not all, experienced other side effects
or what they described as a ‘reaction’ to the medication
which required additional steroid and/or antihistamine in-
jections, for example fainting, skin reactions (itching,
rashes, boils) and an allergic reaction:
“Red spots, well not spots, but boils everywhere.
Small boils everywhere. All my body I feel to
scratch my body. And at the time, I was already














out, so I ran back here. They gave me a Piriton, to
sit down and relax and then it disappeared” (ID 46
IV Hospital/M).
Not all reactions were in terms of welts or itching,
some reported temperature issues after finishing treatment
and the need to try and remedy this before departing from
treatment, 
“For a period of time, I did suffer really bad with
shivers. When I’d finished my treatment, I would
literally be like dithering, and I’d be sat in the car
for a good 20 minutes/ half an hour, with the en-
gine on and the heater blowing. I mentioned it to
the nurses, and they were a bit concerned because
they thought it could be an early stage of a reac-
tion” (ID01 IV Hospital/M).
Side effects were therefore experienced in different
ways by patients, but the concern about it being a prob-
lematic reaction to the treatment itself was common
within these experiences. 
Tiredness and fatigue
Many patients also described feeling tired and/or lethar-
gic immediately after the treatment. One person described
feeling so tired after treatment that they could not help but
sleep for a number of hours post treatment. Fatigue was
therefore for some an unpleasant side effect of treatment: 
“I don’t like, I don’t like that feeling that I know
in about half an hour to an hour’s time, I’ve got to
go to sleep. And I think when your body does that
and you haven’t got a choice, it isn’t a nice feel-
ing.” (ID 36 SC Home/F). 
Overall, patients described feeling tired regardless of
their treatment mode. However, for a couple of patients
the changes in energy levels appeared less of a problem
with SCIg treatment compared with IV. 
Impact on social interactions and relationships
Undergoing Ig treatment impacted upon the social life
and personal relationships of many of the patients and was
another core theme generated from the analysis. The ways
this was experienced is described under three sub-themes
including i) impact upon holidays and travel, ii) missing out
on social activities, and iii) affecting family relationships.
Impact on holidays/travelling 
Having to take treatment regularly and take this time
out meant re-arranging leisure or social activities such as
going on holiday. In addition, as Ig treatment should be
taken every few weeks, patients frequently talked of hav-
ing to plan their treatment around holidays:
“If you went away for three weeks, you’d be ok,
but I think if it was any longer than that, so I don’t
think I can go on a round the world cruise without
making some special arrangements” (ID06 IV
Hospital/M).
Time was therefore seen as being constrained by the
regularity of treatment and the perceived ‘maximum’ time
that patients could be away for on holiday before needing
to make additional provisions to ensure they were able to
access treatment in a different way or place. 
Missing out on social activities
Some described the Ig routines and disruption as being
frustrating and getting them down because they missed
out on other social activities they would prefer to do:
“I suppose on the back of that, the other impact it
had is things like social life and feeling normal
alongside your friends, because I’d go into hospital
once a week, once a fortnight, and probably spend
2 or 3 days recovering from that, just getting to feel
well enough again” (ID24 IV Home/M).
However, some patients did say the treatment itself
did not interfere with their social life, but that they may
have to adapt the type of holidays or activities they did in
order to accommodate treatment.
Affecting family relationships 
Tensions between family members developed, typi-
cally because family members tried to ensure that their
loved ones continued taking their Ig treatment:
“Sometimes it frustrates me, and other times I just
get on with it and do it. It does cause a lot of argu-
ments… if I forget, he’s (partner) like ‘you need
to do you treatment!” (ID49, SC Home/F).
Others felt that treatment impacted on their familial
relationships as it caused their family members to worry
about them more than they might have done had the pa-
tient not been receiving Ig treatment:
“Because their dad died when they were quite
young, they’ve always been really worried then if
I was poorly, so then that was another dimension
that was particularly hard, because I would try not
to let them know so they didn’t worry, and you
know, that sort of thing” (ID41 SC Home/F).
Treatment environment
The place where patients had their Ig treatment added
to the burden, particularly for patients on SCIg at home.
The burden of home treatment related to self-care activi-














ties such as the effort of finding a suitable place to store
the items needed for treatment as well as keeping the
treatment area sterile and clean. The reasons for this was
explained by one woman on SCIg who said: “Because
you can’t put your bottles in the same fridge as a normal
fridge, as your food. So, I have a separate fridge, so that’s
very good (ID40 SC Home/F).
These specific requirements may therefore be a burden
for some, in terms of having the space and resources to
have an additional fridge or space they could keep and
make sterile for their home treatment. 
Some of the participants taking home therapy re-
ported missing the social contact provided by going into
clinic:
“I used to go a day a week into hospital and then
eventually I was on home therapy and that were
fantastic. I do miss, miss them though. I said to
[name deleted] because I used to go in one day a
week, and you get so looked after, and because
you’re chatting to other patients and other people,
and you’re watching all the people, and when you
go on home therapy you do lose that” (ID 36 SC
Home/F).
Emotional burden
There appeared to be a psychological burden associ-
ated with undergoing Ig treatment which this theme de-
scribes. It has four sub-themes including: i) feeling
powerless and depressed, ii) lack of flexibility, iii) fear
about self-injecting and using blood products, and iv) life
revolves around the treatment.
Feeling powerless and depressed 
Emotions ranged from feeling apprehensive about the
treatment to feeling worried and depressed, 
“When it was coming around to treatment, it did
used to depress me like because I know that when
I get it I’m going to be here for like 5 hours or
something like that, and it’s tiring, sat in hospitals”
(ID12 IV Hospital/M):
Others noted feeling powerless in the face of the
treatment they were undergoing and the challenges of
managing that treatment with work and other commit-
ments:
“Because it was depressing me that much, you
know I need to come all time, so I just kept, and I
were working as well. I had to keep having days
off work and stuff like that, and it was getting me
right down like. So, I just thought ‘stuff it’, I
weren’t bothered, and I probably went a few
months, I’ve done it a few times you know” (ID12
IV Hospital/M).
“… it takes out a day and a half of your week, and
it has an impact then on lots of things. If you think
of your week, if you missed out on 36 hours of
your week, I think you’d be, it’s hard to, something
has to give doesn’t it, in that way. Sometimes I can
get a bit, a bit miffed about it” (ID36 SC Home/F).
Fear about self-injecting/using blood products
A number of people discussed having a dislike of nee-
dles and finding the injection and infusion process un-
pleasant both to go through and look at. One patient,
despite having had Ig treatment for a while, described that
he: “… can’t get used to it no, never. I can’t look at it, you
know when they’re putting it in, I can’t look at it at all”
(ID12 IV hospital/M).
Another male participant undergoing IVIg treatment
at home recalled the amount of time it took for him to get
used to the idea of self-injecting:
“I said ‘no chance, I’m not doing that’. I won’t
stick a needle- I can’t look at people stick needles
in me. [Nurse], she persuaded me to have a go at
doing it, which we did. It took 3 or 4 months,
maybe longer.” (ID35 IV Home/M).
A couple of patients voiced concerns about how the
product is made and that there might be a risk that they
could pick up an illness. This particularly related to the fact
that Ig treatment is a blood product and so worries about
contamination and getting an illness such as HIV or AIDS
were expressed, although this was generally accepted as a
risk that was worth taking considering the benefits of the
treatment. However, this in itself led to worries and anxi-
eties about the possibility of the treatment supplies running
out and/or the possibility of switching treatments:
“You know to a new patient, they are going to re-
fuse it, because people they don’t want a medicine
that comes from blood, someone else. People are
afraid… Yes, from someone else, you know like
AIDS and things like that. So, you’re shocked you
know, oh no, no, no, this situation, I don’t want it.
But then you decide to take it because there are no
other options” (ID 46 Iv Hospital/M).
Dependence/life revolves around treatment
Overall, most participants interviewed reported ac-
cepting the treatment as it made them feel better and being
grateful that they had access to this treatment. However,
there was a sense of powerlessness and lack of control
over their treatment regimen. The fact that treatment was
ongoing was viewed as being an emotional challenge that
patients had to accept and manage:
“I thought it was a quick-fix thing. Obviously,
what I didn’t hear, which I’ve now got the grip of,















it has been explained to me, that of course, it isn’t
is it? It’s long-term, well it’s for life basically”
(ID04 IV Hospital/M).
“I have my moments, if I’m honest, when I think
what would really happen if I stopped taking it, be-
cause it’s still even though it’s a million times bet-
ter, there are still times where I just think I wish I
didn’t have to do this” (ID 02 IV hospital/ M).
Those going to hospital felt like they had less control
over when they took their treatment.
A lot of this feeling of powerlessness and lack of con-
trol over their treatment related to the inflexibility of when
they could take the treatment and also their dependence
upon this to stay well for the rest of their lives. Some par-
ticipants expressed a feeling of acceptance that they
would need Ig treatment forever and this would never
change. This feeling of lack of control, was also com-
pounded by the need to be extra vigilant during the infu-
sion sessions for any reactions when receiving this
medication.
Travel 
It was evident that the patients in our study had to in-
vest considerable effort in order to have their Ig therapy.
Another aspect of this related to travelling to clinic ap-
pointments, which this theme and its subtheme i) logisti-
cal factors, relates too - especially for those receiving Ig
treatment in hospital. This was often described as a burden
and inconvenient:
“I phoned them and said ‘look, I’ve been driving
around for 20 minutes, and I cannot find parking
anywhere’. I said ‘I’ve tried the road, I’ve tried in-
side. So if I don’t actually turn up to this appoint-
ment, you know it’s not lack of trying” (ID 47 IV
Hospital/F).
Logistical factors
Logistical factors such as problems finding parking,
travelling long distances, having to rely on others for
transport or using public transport contributed to the treat-
ment burden. Not having to travel for treatment was one
of the reasons cited for preferring home Ig therapy com-
pared to hospital treatment because, as one woman on
IVIg treatment at hospital said: “You think ‘I’ve got to put
a whole day aside just for this…it’s 25 miles” (ID23 IV
Hospital/F). Similarly, another woman on the same treat-
ment described having to set off really early for their treat-
ment: “We had to be up for 6 o’ clock this morning. Well,
ready for 6am” (ID20 IV Hospital/F), and a male partici-
pant shared the challenges of getting to the hospital to un-
dergo his IVIg treatment which involved: “Now, I’m
catching like three buses to get here and it’s taking a lot
longer” (ID12 IV Hospital/M).
Role functioning 
This theme describes the different ways that the par-
ticipants role functioning was negatively affected by the
Ig treatment. Role functioning refers to an individual’s
ability to exercise their day to day duties. This theme had
two sub themes including i) looking after family, and ii)
impact on work/education/school.
Looking after family
Some participants discussed treatment disrupting their
ability to carry out and fulfil their roles in life as they
would like, this could be either as a student, employee or
carer/parent:
“And I’ve got a daughter who’s 17 now. I mean
she was a lot younger then and when you’re in hos-
pital, you’re thinking how they are at home. You
know, X [husband] was working all the time and
X [daughter] had to go between different grand-
parents and things” (ID40 SC Home/F).
“P: Because it were depressing me that much, you
know I need to come all time so I just kept, and I
were working as well. I had to keep having days
off work and stuff like that, and it was getting me
right down like. So I just thought ‘stuff it’, I
weren’t bothered, and I probably went a few
months, I’ve done it a few times you know.
I: Stop taking it?
P: It’s got me down that much like, and because
when I start getting like that, that has an effect at
home, you know what I mean with kids and every-
thing and our lass. So I just stopped going. But
then I started to like feel drained in myself and
everything and get more chest infections and stuff.
Anyway, I’ve always ended up coming back and
that so (ID12 IV Hospital/M).”
Impact on work/education/school
The experiences of stopping work, taking time off
work, adjusting working hours for appointments and treat-
ment varied across participants depending on age, type of
work/study and their employer but sometimes this could
have had long-lasting effects on their lives where they felt
unable to fulfil their life time goals:
“Well it was difficult because first being diagnosed
and going into you can imagine like the critical
years in your education, so like 15/16, going on to
17, and trying to do GCSE’s and other things when
I’d had periods of time for the two or three years
before that out of school for investigation pur-
poses. That had quite a massive impact really”
(ID24 IV Home/M).















The opportunity to be promoted or advance in careers
was therefore seen as being restricted by the need for Ig
treatment. Those on home SCIg treatment found that they
needed to take less time out of work than when having
treatment at the hospital and overall that it was less dis-
ruptive to the other roles they needed to fulfil, although
they often still had to adapt their work lives or their per-
sonal lives as partner or spouse to accommodate their
treatment, as one male participant on IVIg treatment at
home shared:
“That is my greatest frustration and it frustrates me
as well because of like future implications, be-
cause I don’t think I- it’s going to be a hell of a
nightmare for me to progress within a company,
and yes that’s about it really” (ID13 IV Home/M).
Financial consequences 
In the UK, the National Health Service (NHS) covers
the direct cost of Ig treatment. Therefore, it was not sur-
prising that this was the least reported aspect of Ig treat-
ment burden for the patients interviewed. However,
several indirect costs were identified through the inter-
views, which are encompassed within this theme and its
three sub themes, including travel cost, insurance and loss
of earnings. 
Travel was cited as the main indirect cost of treatment
for those on IVIg hospital treatment depending on the dis-
tance travelling and mode of transport, as highlighted by
two male participants who explained: “So I virtually got
30 to 40 miles worth of petrol, plus £3.70 to park. So
that’s what the cost” (ID06 IV hospital/M), and “It is a
pain to be fair, parking every time I come. It’s not as bad
now, but when I used to have the sub-cut, and I used to
come to the hospital, it’s like £5 every week” (ID02 IV
Hospital/M).
Whilst travelling to hospital was considered expen-
sive, travelling overseas for holidays and work was also
hindered due to the inability to get travel insurance, as
highlighted in one exemplar quote from a male participant
who receives IVIg treatment in hospital:
“I’ve had opportunities to go over to America,
working over there, and I’m like I’ve got to have
treatment, and travel insurance and that, they’re
not going to cover the cost of this treatment. For
me to pay for it, it’s probably really, from a finan-
cial standpoint- it’s just causing me a lot of prob-
lems really” (ID01 IV Hospital/M).
The relapsing nature of the condition and the necessity
to have more treatment and hospital visits also impacted
on work for many of the participants, with some describ-
ing how they were forced to leave work or feeling afraid
that this may happen, as reported below by one female
participant on SCIg at home and one male participant on
IVIg in hospital:
“At the time, I was very career-minded. I got a re-
ally, I got a really good job at the local authority
at ————- Council, and I was quite high up. But
then at that time, I was getting worse and worse
and worse and I was having time and time off
work. And obviously you can’t have, so I was
forced to leave my work” (ID36 SC Home/F).
“It does bother me. It does because what they’ll do
is they’ll sack me. That’s it, that’s the bottom line.
That’s the way they are. It’s cost-cutting isn’t it.
I’ve been there so long. I earn the most money of
my grade amongst about 8 or 9 of us. If they can
see a chance, you’re gone, and that’s what they’ll
use to get rid of me. But it’s not my fault, and I’ve
tried to explain this to them” (ID04 IV
Hospital/M).
The burden of treatment therefore created worries in
relation to work and the ability to fulfil employment, and
this was a cause for concern in terms of the long-term fi-
nancial consequences for patients if they were unable to
work or had to reduce the number of hours they worked. 
Discussion
Our study aim was to explore PID patient’s experi-
ences of the burden of Ig treatment, including those re-
ceiving IVIg and SCIg, either in a home or hospital
setting. To the best of our knowledge, this is the first study
which has solely sought to explore in-depth the potential
burden of Ig treatment for this patient group. To do this
we adhered to the concept of burden of treatment such
that we sought to explore where receiving Ig therapy may
cause work and effort for the patient. In this study, Burden
of Treatment (BoT) was defined as the consequences of
receiving treatment (these may be medication, therapies,
or other interventions). This concept also entailed the
“work of being a patient”—everything the patient needs
to do to treat and manage their illness, for example, un-
dergoing tests and investigations, visiting doctors, adher-
ing to treatment regimens, and making lifestyle changes.23
Whilst all the patients had experienced improvements
in their health-related quality of life as a consequence of
Ig treatment, they also describe areas of the treatment that
are burdensome and impact upon a wide spectrum of life
domains. These burdens particularly related to the amount
of time, organization and planning that is needed. They
also faced numerous physical, social, relationship, emo-
tional, role, travelling, and financial challenges in their ef-
fort to undergo and maintain their infusions and care for
their health. Our findings concurred with the results of the
quantitative studies in this area.13-22We found the biggest
burden of Ig therapy was in relation to time, with over two
thirds of patients reporting this as a treatment burden. 
Overall, the patients had experienced some mild sys-















temic reactions to the therapy as expected,31 although a
couple of patients had reported more extreme reactions to
their treatment. Immediate systemic reactions with IVIg
therapy are usually mild but include head and body aches,
chills and fever. Allergic reactions are uncommon.6Other
more serious reactions can include headache, aseptic
meningitis, kidney failure, blood clots and haemolytic re-
actions.32 There is also a risk of more variable blood levels
of IgG compared to the subcutaneous route of adminis-
tration. A low trough IgG level prior to intravenous infu-
sion can result in patients experiencing symptoms of
fatigue, general malaise and increased susceptibility to in-
fection.32 Systemic adverse reactions to SCIg are also rare,
however local adverse reactions such as persistent pain,
bruising, swelling and erythema are common.31
In our study, there were different descriptions in the
reports of treatment burden between the modes of treat-
ment (SCIg and IVIg) and whether people had treatment
at home or in hospital. A systematic literature review and
a meta-analysis concluded that the efficacy of SCIg re-
placement was similar to IVIg treatment, however better
treatment satisfaction, quality of life, and faster recovery
(e.g. reduced time off work) was also observed.33
From the qualitative accounts of treatment that sur-
faced in our study, SCIg at home was associated with re-
duced travel, time and financial burden, greater comfort
(both physically and in terms of being in a home environ-
ment) and less disruption to social activities. 
Howard et al.14 reported that IV immunoglobulin treat-
ment was burdensome for patients because of issues
around scheduling therapy and travel. Gardulf et al.19 re-
ported that patients on SCIg at home reported a signifi-
cantly increased ability to participate in recreational
activities. Similarly, Daly et al.,13 found that patients un-
dergoing home-based treatment (Sandoglobulin) had bet-
ter Life Quality Index scores than clinic-based patients.
Perceived benefits included greater convenience, comfort,
independence, freedom to travel, flexibility of treatment
schedule and a more pleasant treatment atmosphere.
Home treated patients also reported less disruption of
daily activities, waiting time and treatment-associated
travel and cost.
However, whilst some of these benefits were experi-
enced by the patients in our study, we also found there
were areas where SCIg at home did cause a burden par-
ticularly in relation to the treatment environment (e.g. the
need to have an infusion partner present during treatment,
maintaining a clean and sterile environment in their
homes, and lack of social contact that the hospital envi-
ronment provided). 
An infusion partner is someone close to the patient
(e.g. a relative, a partner or friend) who is prepared to sup-
port the patient with their infusions. In the UK, the current
consensus is that patients infusing via the subcutaneous
route do not require an infusion partner, however deci-
sions are made following an individual assessment. For
example, some patients receiving subcutaneous infusions
may still require an infusion partner e.g. due to lack of
dexterity for using the equipment. If an infusion partner
is identified then they are requested to attend a number of
CIAU competency-based training sessions to enable them
to carry out certain aspects of the infusion. These sessions,
cover all aspects of the infusion, but focus on their role as
the infusion partner. The aim is to have the training pro-
gramme completed in 4-6 weeks however everyone is as-
sessed individually and trained to meet their individual
needs. The actual length of training will depend on the
rate of learning. This person has to undergo a number of
weeks of training to allow the person to infuse at home
rather than in clinic. Thus, the level of support varies. In
the UK, it is also not routine to actively carry out pre-
home visits. Instead, how and where infusions take place
is typically discussed with their healthcare professional
and the patient and partner.
Patients undergoing their Ig treatment at the CIAU felt
that the clinical team took on these considerations and
therefore they did not need to worry. It was notable that
the staff at the clinic went out of their way to accommo-
date people for their needs and that overall people had
very positive experiences at the clinics.
A couple of conceptual models have recently been
proposed to describe burden of treatment.9,24 Although
generated from a sample of patients with complex health
conditions and therefore undergoing a variety of different
medical treatment regimes, Eton et al.24 identified three
broad themes; i) the work patients must do to care for their
health, ii) problem focused strategies and tools to facilitate
the work of self-care and iii) factors that exacerbate per-
ceived treatment burden (i.e., challenges taking medica-
tion, emotional problems with family and friends, role and
activity limitations, financial challenges, confusion about
medical information, systemic obstacles of health care de-
livery. Similarly, Sav et al.9 presented four themes on the
burden of treatment with chronic disease relating to finan-
cial burden, time and travel burden, medication burden
and healthcare access burden.
In our study, these models were not used as a frame-
work for the analysis because we adopted an inductive,
data driven approach. However, our identified themes
generally support the previous generic conceptual frame-
works on burden of treatment previously mentioned.9,24
One notable difference to Sav et al.’s9 findings was that
we found concerns around financial issues to be the least
burdensome. However, this different finding is likely be-
cause Sav et al.’s9 research was conducted in Australia
where the healthcare system is funded differently to the
UK. Studies that have measured the burden of Ig treat-
ment in a non-UK population have also found issues
around costs and insurance to be a problem.14 Indeed, in
the previous chronic condition literature, the healthcare
system in which a treatment is given affects the perceived
burden of the treatment. 















Another notable difference to Sav et al.’s9 findings
were the emotional, relationship and social burden
themes. Although generated from a sample of patients
with complex health conditions and therefore undergoing
a variety of different medical treatment regimes, Eton et
al.34 reported that emotional problems with family and
friends, role and activity limitations were some of the fac-
tors that could exacerbate perceived treatment burden.
However, the psychological burden of the treatment was
also largely underexplored. Also, in relation to the frame-
work proposed by Eton et al.,24 we only identified a cou-
ple of provider level issues but this may be because we
recruited from one unit where the patients had very good
relationships with their staff. The patients also didn’t seem
to be confused about any aspects of their Ig treatment.
To our knowledge this study provides the first in-depth
qualitative study of patient’s experiences of the burden of
both IVIg and SCIg treatment for PID.25 In focusing upon
the work and effort that PID patients describe needing to
undertake to receive this treatment, there may be some
positive experiences of receiving this treatment that have
not been reported or described by the patient. However,
it is worth stating that despite the burdensome aspects of
Ig treatment reported in this paper, there was an over-
whelming sense of gratitude that Ig treatment is available
to help manage their chronic condition which would not
be possible without it. The sample size is modest but is
expected for a qualitative piece of research and data sat-
uration was reached. We recruited all the patients from
one hospital in the UK. It may be that there are aspects of
treatment burden that were not reported in this population,
and patients in other sites or countries may have different
experiences. This is particularly relevant in relation to the
financial burden associated with Ig treatment as all the pa-
tients had their Ig treatment paid for by the NHS which is
free at the point of treatment. The perceived level of bur-
den upon leisure and social activities (in particular, holi-
days) described by some IVIg patients in this study may
also be less for those being treated in other parts of the
world. Local practice is not to switch between IVIg and
SCIg products if possible. However, every effort is made
to accommodate patients’ holiday arrangements and
arrange IVIg infusions (for patients on IVIg) around these.
Whilst longer periods of travel has necessitated more
planning, this has also been accommodated by liaising
with local immunologists in the holiday destinations. 
For patients on SCIg home therapy, local practice is
that patients can take their product with them, so it should
not interfere with holiday arrangements and letters for
plane travel are also provided if required. As the patients
on IVIg therapy described the treatment as causing more
burden to their holidays, it would be interesting to explore
this further, with the aim of identifying the ways this felt
burden could potentially be reduced further in the local
setting. 
Our sample of patients included more patients who
were undergoing IVIg treatment (n = 21) compared to
only nine patients who were receiving SCIg. The differ-
ence in sample numbers is because, at the time the study
was conducted, the CIAU were treating more patients on
IVIg therapy than SCIg. In addition, fewer home therapy
patients returned the consent forms through the post. More
IVIg patients were recruited because they were given their
consent forms whilst attending for treatment at the clinic.
This could mean that there’s a bias towards those on IVIg
hospital treatment in the results which may have occurred
as a result of enhanced trust established while meeting the
researchers. Although our reflexive thematic analysis il-
luminated patient perspectives, further research might use
other methodologies, such as discourse analysis, to exam-
ine how patient accounts are [co] constructed in interview
settings, thereby highlighting the interactional nature of
interview data, and/or to analyse consultations between
health care professionals and patients to explore how pa-
tient burden is negotiated in situ.35
The choice of which route to use for Ig administration
depends upon the personal preference of the patient, ease
of intravenous access, tolerability of any previous Ig prod-
ucts, and the patient’s lifestyle. It can be reviewed regu-
larly and adjusted throughout the period of treatment as a
patient’s circumstances change. To further support pa-
tients in this decision-making process and improve pa-
tient-centred care plans, it may be beneficial for
healthcare providers to share and discuss the potential
work and effort for the patient that Ig treatment may result
in. In turn, this may further help providers to deliver min-
imally disruptive medicine by tailoring treatment regi-
mens to the realities of the daily lives of patients and
relevant patient goals.36 Patients are likely to benefit from
education to encourage them to acknowledge any felt
treatment burden and talking with their health care
provider about what can be possibly done to reduce it,
which might foster adherence.37 It should also be noted
that experts believe increased patient and physician shared
decision-making (SDM) can result in better overall lon-
gitudinal care but understanding the physician’s role in
facilitating SDM is still limited, hence should be further
explored.38
Most patients and healthcare providers are aware of
treatment burden, however the lack of a simple method to
measure it in the clinical setting often results in lack of
focus on this important aspect of patient - centred care.
As identified in a previous systematic review, many in-
struments are available to measure patient treatment bur-
den, however there is no one standardized assessment
method. To measure treatment burden, a few generic bur-
den of treatment questionnaires are currently available,
but these have been designed to capture treatment burdens
across a wide range of chronic illnesses, for example, the
Patient Experience with Treatment and Self-Management
questionnaire.34 Some of the patient’s perceived Ig treat-
ment burdens we identified would be captured in this
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measure e.g. role and social activity limitations, however
others would not in particular their described accounts of
fear and worry about needles, catching another illness
from the blood product, and other specific psychological
and physical consequences associated with their Ig treat-
ment. One of the key differences is that these generic
questionnaires ask questions in relation to ‘medications’
but for the Ig group, their treatment is infusion based and
so some of questions and the phrasing of these are not rel-
evant to this PID cohort of patients.
As people live longer with chronic conditions there is
an increased need for identification of patients as well as
their caregivers burdened by specific treatment in order
to engage in approaches to reduce treatment burden effec-
tively. A standard and validated assessment method to
measure patients’ with PID and their caregivers’ treatment
burden in the clinical setting might not only enhance treat-
ment but also allow for comparison of different ap-
proaches to reducing PID treatment burden and foster
ongoing evaluation and monitoring of burden across pa-
tient populations and time. More importantly, given that
the existing generic burden of treatment questionnaires do
not appear to capture all of the Ig specific treatment-re-
lated burdens, we have used the themes identified from
this qualitative work to inform the development of a new
condition-specific Ig burden of treatment measure for this
patient group (IgBoT-35) that is applicable across the dif-
ferent modes of administration and treatment types (IVIg
and SCIg).39 This also follows good practice which rec-
ommends that data generated from qualitative research
with the patient group of interest is used to develop the
items in a patient-reported outcome measure to ensure its
content validity.40
Conclusions
In this qualitative study, we have explored the experi-
ences of undergoing life-long Ig treatment as described by
patients diagnosed with a PID. In doing so, it has provided
the first in-depth, rich account of Ig treatment burden and
has shown that the therapy can impact upon many areas of
life – particularly in relation to the amount of time the ther-
apy necessitates for PID patients on IVIg and SCIg treat-
ment. There appear to be some qualitative differences
between patient’s accounts and experiences of the burden
of IVIg treatment compared to SCIg treatment but larger
studies are needed to confirm this. For example, IVIg treat-
ment in hospital was associated with more travel burden
than SCIg at home. But SCIg necessitated more work and
effort to keep a sterile and clean environment and thus re-
quired more planning and organisation in this regard.
Choice over treatment should be informed by patient’s clin-
ical and lifestyle needs as well as familiarity with treatment
regime. To facilitate this, our advice is that healthcare
providers should also discuss with their patients the differ-
ent ways that Ig treatment can be burdensome so the pa-
tient’s personal circumstances and preferences can be ac-
commodated. Whilst healthcare delivery advocates the use
of tools in routine care that can assess quality of life, we
also recommend this is supplemented with a standardised
treatment burden outcome measure such as the IgBoT-35
as part of their routine clinical practice as this can further
facilitate the monitoring and delivery of more effective and
personalised patient-centred care to their PID patients in
the future. 
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